QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 why-is-clearside-biomedical-stock-gaining-today

Clearside Biomedical pioneers suprachoroidal drug delivery for precise, effective treatment of retinal diseases. Oppenheimer ra...

 oppenheimer-initiates-coverage-on-clearside-biomedical-with-outperform-rating-announces-price-target-of-5

Oppenheimer analyst Andreas Argyrides initiates coverage on Clearside Biomedical (NASDAQ:CLSD) with a Outperform rating and ...

 clearside-biomedical-announces-publication-of-consensus-guidelines-for-drug-delivery-via-suprachoroidal-space-injection-in-peer-reviewed-industry-journal-retina

Expert Panel of Ophthalmologists Developed Professional Guidelines in Using the Innovative Technique for Retinal Therapeutic ...

 hc-wainwright--co-maintains-buy-on-clearside-biomedical-lowers-price-target-to-5

HC Wainwright & Co. analyst Yi Chen maintains Clearside Biomedical (NASDAQ:CLSD) with a Buy and lowers the price target ...

 needham-reiterates-buy-on-clearside-biomedical-maintains-4-price-target

Needham analyst Serge Belanger reiterates Clearside Biomedical (NASDAQ:CLSD) with a Buy and maintains $4 price target.

 clearside-biomedical-q1-2024-gaap-eps-017-misses-014-estimate-sales-230000k-miss-585000k-estimate

Clearside Biomedical (NASDAQ:CLSD) reported quarterly losses of $(0.17) per share which missed the analyst consensus estimate o...

 needham-reiterates-buy-on-clearside-biomedical-maintains-4-price-target

Needham reiterates Clearside Biomedical (NASDAQ:CLSD) with a Buy and maintains $4 price target.

 hc-wainwright--co-reiterates-buy-on-clearside-biomedical-maintains-6-price-target

HC Wainwright & Co. analyst Yi Chen reiterates Clearside Biomedical (NASDAQ:CLSD) with a Buy and maintains $6 price target.

 jmp-securities-reiterates-market-outperform-on-clearside-biomedical-maintains-5-price-target

JMP Securities analyst Jonathan Wolleben reiterates Clearside Biomedical (NASDAQ:CLSD) with a Market Outperform and maintain...

 wedbush-maintains-outperform-on-clearside-biomedical-lowers-price-target-to-4

Wedbush analyst Liana Moussatos maintains Clearside Biomedical (NASDAQ:CLSD) with a Outperform and lowers the price target f...

 needham-reiterates-buy-on-clearside-biomedical-maintains-4-price-target

Needham analyst Serge Belanger reiterates Clearside Biomedical (NASDAQ:CLSD) with a Buy and maintains $4 price target.

 clearside-biomedical-q4-2023-adj-eps-008-beats-009-estimate-sales-630m-beat-443m-estimate

Clearside Biomedical (NASDAQ:CLSD) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of ...